| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Presented Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 | 74 | PR Newswire | - CAHtalyst Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults- Phase 2 Study for Modified-Release Hydrocortisone in Adults... ► Artikel lesen | |
| 09.05. | How Neurocrine, An IBD 50 Stock, Is Stacking Up Wins In 2024 - And Outperforming Peers | 7 | Investor's Business Daily | ||
| 09.05. | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults | 48 | PR Newswire | SAN DIEGO, May 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability... ► Artikel lesen | |
| 09.05. | Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults | 104 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 9 May 2024 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. ("Neurocrine"; Nasdaq: NBIX), a leading neuroscience-focused... ► Artikel lesen | |
| 08.05. | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults | 51 | PR Newswire | SAN DIEGO, May 8, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability... ► Artikel lesen | |
| 02.05. | Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript | 4 | Insider Monkey | ||
| 02.05. | Earnings call: Neurocrine Biosciences reports robust Q1 growth, pipeline advances | 8 | Investing.com | ||
| 01.05. | Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences | 2 | Benzinga.com | ||
| 01.05. | Neurocrine Q1 revenue beats Street, gets FDA okay for Ingrezza Sprinkle | 4 | Seeking Alpha | ||
| 01.05. | Neurocrine bags FDA approval for new 'sprinkle' Ingrezza formulation | 2 | Pharmaceutical Technology | ||
| 01.05. | Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech | 2 | Investor's Business Daily | ||
| 01.05. | No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win | 4 | Investor's Business Daily | ||
| 01.05. | Neurocrine Biosciences shares jump 3% on earnings, revenue beat | 5 | Investing.com | ||
| 01.05. | Neurocrine Biosciences Inc Q1 Earnings Summary | 202 | AFX News | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Neurocrine Biosciences Inc (NBIX):Earnings: $43.4 million in Q1 vs. -$76.6 million in the same period last year.
EPS: $0.42 in... ► Artikel lesen | |
| 01.05. | Neurocrine Biosciences Non-GAAP EPS of $1.20 misses by $0.09, revenue of $515.3M beats by $3.29M | 3 | Seeking Alpha | ||
| 01.05. | NEUROCRINE BIOSCIENCES INC - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 01.05. | NEUROCRINE BIOSCIENCES INC - 8-K, Current Report | 3 | SEC Filings | ||
| 01.05. | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Reports First Quarter 2024 Financial Results | 46 | PR Newswire | INGREZZA® (valbenazine) First Quarter Net Product Sales of $506 Million Representing 23% Year-Over-Year Growth
INGREZZA® SPRINKLE (valbenazine) Capsules Approved by the U.S. FDA
Crinecerfont New Drug... ► Artikel lesen | |
| 01.05. | FDA Approves Neurocrine Biosciences' INGREZZA Sprinkle Capsules | 358 | AFX News | WASHINGTON (dpa-AFX) - The U.S. Food and Drug Administration has approved INGREZZA Sprinkle (valbenazine) capsules, a new oral granules formulation of INGREZZA (valbenazine) capsules prescribed... ► Artikel lesen | |
| 30.04. | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules | 184 | PR Newswire | SAN DIEGO, April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) capsules... ► Artikel lesen |
Seite:
1 2 3 4 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 5.471 |
| EVOTEC | 4.722 |
| TUI | 3.556 |
| NEL | 2.749 |
| PLUG POWER | 2.137 |
| BAYER | 2.127 |
| NVIDIA | 2.086 |
| AMC ENTERTAINMENT | 2.070 |
| SIEMENS ENERGY | 1.944 |
| RHEINMETALL | 1.897 |
| DEUTSCHE BANK | 1.687 |
| RENK GROUP | 1.430 |
| SIEMENS | 1.369 |
| COMMERZBANK | 1.350 |
| HEIDELBERGER DRUCK | 1.293 |
| ALIBABA | 1.285 |
| AIXTRON SE | 1.282 |
| VOLKSWAGEN | 1.140 |
| MERCEDES-BENZ | 1.122 |
| BYD | 1.114 |
| DEUTSCHE TELEKOM | 1.072 |
| SUPER MICRO COMPUTER | 1.072 |
| RWE | 1.042 |
| ALLIANZ | 1.014 |
| DEUTSCHE LUFTHANSA | 952 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
